AR108558A2 - Método para preparar ácido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico - Google Patents
Método para preparar ácido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílicoInfo
- Publication number
- AR108558A2 AR108558A2 ARP170101388A ARP170101388A AR108558A2 AR 108558 A2 AR108558 A2 AR 108558A2 AR P170101388 A ARP170101388 A AR P170101388A AR P170101388 A ARP170101388 A AR P170101388A AR 108558 A2 AR108558 A2 AR 108558A2
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- oxo
- acid
- naphthyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Métodos para preparar ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico. También composiciones farmacéuticas que comprenden ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y métodos de tratamiento que utilizan dichas composiciones. Reivindicación 1: Un proceso para preparar ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico, caracterizado porque comprende: i) abrir el epóxido del compuesto de fórmula (1) con metilamina para obtener el compuesto de fórmula (2), ii) resolver el compuesto de fórmula (2) con un ácido quiral seleccionado de ácido L-(-)-málico y ácido L-(-)-piroglutámico para obtener el compuesto de fórmula (3) ó (4), iii) proteger la amina secundaria del compuesto de fórmula (3) ó (4) con el grupo protector ter-butoxicarbonilo para obtener el compuesto de fórmula (5), iv) metilar el grupo hidroxilo libre del compuesto de fórmula (5) con un agente de metilación, v) desproteger los grupos amino con monohidrato de ácido p-toluensulfónico para obtener el compuesto de fórmula (6), vi) hacer reaccionar el compuesto de fórmula (6) con el compuesto de fórmula (7) para obtener ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico. Reivindicación 42: Un compuesto caracterizado porque se selecciona de los compuesto de fórmula (3) ó (4).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14185608P | 2008-12-31 | 2008-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108558A2 true AR108558A2 (es) | 2018-08-29 |
Family
ID=42103392
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090105186A AR074962A1 (es) | 2008-12-31 | 2009-12-30 | Metodo para preparar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxilico |
ARP170101388A AR108558A2 (es) | 2008-12-31 | 2017-05-23 | Método para preparar ácido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090105186A AR074962A1 (es) | 2008-12-31 | 2009-12-30 | Metodo para preparar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxilico |
Country Status (19)
Country | Link |
---|---|
US (4) | US8497282B2 (es) |
EP (2) | EP3284745A1 (es) |
JP (3) | JP6129471B2 (es) |
KR (2) | KR20170090535A (es) |
CN (1) | CN102341393B (es) |
AR (2) | AR074962A1 (es) |
AU (3) | AU2009335159B2 (es) |
BR (1) | BRPI0923780A2 (es) |
CA (1) | CA2748066C (es) |
ES (1) | ES2646093T3 (es) |
IL (1) | IL213708A (es) |
MX (1) | MX2011006974A (es) |
NZ (1) | NZ593763A (es) |
RU (2) | RU2015106671A (es) |
SG (2) | SG10201504789RA (es) |
TW (1) | TWI469980B (es) |
UA (1) | UA108194C2 (es) |
WO (1) | WO2010078294A1 (es) |
ZA (2) | ZA201104610B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3053579A1 (en) | 2004-03-15 | 2016-08-10 | Sunesis Pharmaceuticals, Inc. | Use of sns-595 for treating ovarian cancer |
US20100048609A1 (en) * | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
WO2009054935A1 (en) | 2007-10-22 | 2009-04-30 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
US20110008371A1 (en) | 2007-12-10 | 2011-01-13 | Sunesis Pharmaceuticals, Inc | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
WO2011056566A2 (en) * | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
EP3826613A4 (en) * | 2018-08-31 | 2022-05-04 | Sun Pharmaceutical Industries Limited | PARENTERAL DOSAGE FORM OF CARBOPLATIN |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6233176A (ja) | 1985-08-05 | 1987-02-13 | Toyama Chem Co Ltd | 1,4−ジヒドロ−4−オキソナフチリジン誘導体およびその塩 |
JP2995704B2 (ja) * | 1989-02-17 | 1999-12-27 | 東京化成工業株式会社 | 光学活性な1h−3−アミノピロリジン化合物の製造法 |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
JP3312459B2 (ja) * | 1993-12-28 | 2002-08-05 | 東レ株式会社 | 光学活性アミンの単離方法 |
RO117793B1 (ro) * | 1994-06-14 | 2002-07-30 | Dainippon Pharmaceutical Co | Derivati de acid piridoncarboxilic si compozitie farmaceutica care ii contine |
JP4323574B2 (ja) | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
JPH10173986A (ja) | 1996-12-16 | 1998-06-26 | Sony Corp | 移動体撮影装置 |
JP4294121B2 (ja) | 1998-06-05 | 2009-07-08 | 大日本住友製薬株式会社 | ピリドンカルボン酸誘導体の製造方法およびその中間体 |
JP4178783B2 (ja) | 2001-10-19 | 2008-11-12 | 三菱化学株式会社 | 光学記録媒体 |
EP3053579A1 (en) | 2004-03-15 | 2016-08-10 | Sunesis Pharmaceuticals, Inc. | Use of sns-595 for treating ovarian cancer |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
WO2007146335A2 (en) * | 2006-06-12 | 2007-12-21 | Sunesis Pharmaceuticals, Inc. | Compounds and compositions for treatment of cancer |
US20100048609A1 (en) * | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
US7790274B2 (en) | 2006-08-02 | 2010-09-07 | High Impact Technology, Llc | Layered panel structure including self-bonded thermoformable and non-thermoformable layer materials |
US20080063642A1 (en) * | 2006-08-02 | 2008-03-13 | Adelman Daniel C | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders |
WO2009054935A1 (en) * | 2007-10-22 | 2009-04-30 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
US20110008371A1 (en) * | 2007-12-10 | 2011-01-13 | Sunesis Pharmaceuticals, Inc | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
SG10201400258SA (en) | 2009-02-27 | 2014-05-29 | Sunesis Pharmaceuticals Inc | Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 Activity |
UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
WO2011056566A2 (en) | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
-
2009
- 2009-12-29 SG SG10201504789RA patent/SG10201504789RA/en unknown
- 2009-12-29 KR KR1020177021219A patent/KR20170090535A/ko not_active Application Discontinuation
- 2009-12-29 NZ NZ593763A patent/NZ593763A/xx not_active IP Right Cessation
- 2009-12-29 UA UAA201109496A patent/UA108194C2/uk unknown
- 2009-12-29 JP JP2011544574A patent/JP6129471B2/ja active Active
- 2009-12-29 RU RU2015106671/04A patent/RU2015106671A/ru not_active Application Discontinuation
- 2009-12-29 CN CN200980157710.2A patent/CN102341393B/zh not_active Expired - Fee Related
- 2009-12-29 SG SG2011048444A patent/SG172457A1/en unknown
- 2009-12-29 KR KR1020117017736A patent/KR101765956B1/ko active IP Right Grant
- 2009-12-29 WO PCT/US2009/069645 patent/WO2010078294A1/en active Application Filing
- 2009-12-29 MX MX2011006974A patent/MX2011006974A/es active IP Right Grant
- 2009-12-29 BR BRPI0923780-1A patent/BRPI0923780A2/pt not_active IP Right Cessation
- 2009-12-29 RU RU2011132119/04A patent/RU2548031C2/ru not_active IP Right Cessation
- 2009-12-29 EP EP17179724.4A patent/EP3284745A1/en not_active Withdrawn
- 2009-12-29 ES ES09796587.5T patent/ES2646093T3/es active Active
- 2009-12-29 AU AU2009335159A patent/AU2009335159B2/en not_active Ceased
- 2009-12-29 EP EP09796587.5A patent/EP2382214B1/en not_active Not-in-force
- 2009-12-29 CA CA2748066A patent/CA2748066C/en not_active Expired - Fee Related
- 2009-12-30 AR ARP090105186A patent/AR074962A1/es not_active Application Discontinuation
- 2009-12-30 US US12/650,390 patent/US8497282B2/en not_active Expired - Fee Related
- 2009-12-31 TW TW98146462A patent/TWI469980B/zh not_active IP Right Cessation
-
2011
- 2011-06-21 IL IL213708A patent/IL213708A/en not_active IP Right Cessation
- 2011-06-22 ZA ZA2011/04610A patent/ZA201104610B/en unknown
-
2012
- 2012-10-05 ZA ZA2012/07483A patent/ZA201207483B/en unknown
-
2013
- 2013-07-11 US US13/940,157 patent/US8802719B2/en not_active Expired - Fee Related
-
2014
- 2014-07-11 US US14/329,765 patent/US20150157614A1/en not_active Abandoned
-
2015
- 2015-06-09 JP JP2015116753A patent/JP6174627B2/ja not_active Expired - Fee Related
- 2015-07-24 AU AU2015205924A patent/AU2015205924A1/en not_active Abandoned
-
2016
- 2016-03-08 US US15/064,498 patent/US9839630B2/en not_active Expired - Fee Related
-
2017
- 2017-05-23 AR ARP170101388A patent/AR108558A2/es unknown
- 2017-06-08 AU AU2017203865A patent/AU2017203865A1/en not_active Abandoned
- 2017-07-06 JP JP2017132768A patent/JP2017214400A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108558A2 (es) | Método para preparar ácido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico | |
CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
AR040335A1 (es) | Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto | |
PE20081583A1 (es) | Agentes antibacterianos derivados de compuestos carbonilamino | |
BRPI0908120A8 (pt) | Compostos que são inibidores de erk, composição faramacêutica e uso | |
AR055057A1 (es) | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. | |
PE20091331A1 (es) | Composiciones farmaceuticas que comprenden polimeros de amina reticulada | |
AR050267A1 (es) | Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
BRPI0506843A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
BRPI0713923B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica compreendendo os referidos compostos, método de preparação de um composto, e uso dos mesmos | |
BRPI0206433B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
UY28821A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos. | |
PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
UY29301A1 (es) | Derivados amida | |
BRPI0612957B8 (pt) | composto, processos de preparação de compostos, composição farmacêutica e uso de um composto | |
AR064833A1 (es) | Un procedimiento para la preparacion de vildagliptin | |
BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
AR065017A1 (es) | Procedimiento para la preparacion de betamimeticos | |
MX2012006490A (es) | Inhibidores azociclicos de hidrolasa de amidas de acidos grasos. | |
TN2019000170A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
PE20091359A1 (es) | Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina | |
ME00680B (me) | Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže | |
IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |